Artelo Biosciences

Contributing Author

Recent Articles by Artelo Biosciences

5 hours	Artelo Biosciences Announces Positive Preclinical Efficacy with ART12.11 in Stress-Induced Depression Model ARTL +53.23% GlobeNewswire
Jun-30	Artelo Biosciences Announces Positive First-in-Human Data for ART26.12, a Novel Non-Opioid Treatment Candidate for Persistent Pain ARTL GlobeNewswire
Jun-26	Artelo Biosciences Announces $1.425 Million At-the-Market Private Placement Financing ARTL GlobeNewswire
Jun-11	Artelo Biosciences Announces Reverse Stock Split ARTL GlobeNewswire
Jun-05	Artelo's Fatty Acid Binding Protein 5 Inhibitor, ART26.12, Compares Favorably to Naproxen in an Osteoarthritis Pain Study ARTL GlobeNewswire
Jun-02	New Independent Review Paper Strengthens Therapeutic Rationale for Artelo's FABP Inhibitor Program in Anxiety and Depression ARTL GlobeNewswire
May-13	Artelo Biosciences Provides Business Update and Reports First Quarter 2025 Financial Results ARTL GlobeNewswire